<DOC>
	<DOCNO>NCT01971632</DOCNO>
	<brief_summary>The primary objective demonstrate superiority OXN placebo time initial dose study medication multiple pain event ( inadequate analgesia ) double blind phase .</brief_summary>
	<brief_title>A Randomised , Double Blind , Placebo Active Controlled , Double Dummy , Parallel Group Study Determine Safety Efficacy Oxycodone/Naloxone Prolonged Release Tablets Subjects With Moderate Severe , Chronic Nonmalignant Pain</brief_title>
	<detailed_description />
	<mesh_term>Naloxone</mesh_term>
	<mesh_term>Oxycodone</mesh_term>
	<criteria>Inclusion Criteria Subjects meet follow criterion include study : 1 . Males female least 18 year age ( Females less one year postmenopausal negative serum urine pregnancy test record within 72 hour prior first dose study medication , nonlactating , willing use adequate reliable contraception throughout study. ) . 2 . Documented history moderate severe chronic pain low back required aroundtheclock opioid therapy . 3 . Nonmalignant low back pain adequately manage opioid analgesic least past 2 week . 4 . Subjects require continuation daily opioid analgesic treatment likely benefit chronic opioid therapy duration study . 5 . Subjects willing able participate aspect study , include use oral medication , completion subjective evaluation , attend schedule clinic visit , complete telephone contact , compliance protocol requirement evidence provide write , informed consent . Amendment No . 1 , date 28Sep2004 prior FPFV , change inclusion criterion Bullet 3 : Nonmalignant low back pain ( example osteoarthrosis / osteoarthritis spine , deform spondylosis , spondylolisthesis , disc herniation / sciatica , spinal stenosis ) adequately manage opioid analgesic least past 2 week . Bullet 4 : Subjects require continuation daily opioid analgesic treatment likely benefit chronic opioid therapy ( WHO step III opioid ) duration study . ( See Section 9.8.1 ) Any amendment protocol include Appendix 16.1.1.1 . Exclusion Criteria Subjects meet follow criterion exclude study : 1 . Any history hypersensitivity oxycodone , naloxone , related product . 2 . Subjects currently take equivalent &lt; 10 mg &gt; 40 mg/d oxycodone ( Refer Appendix 12.2 protocol : Drug Conversion Tables. ) . 3 . Subjects diagnose cancer , include basal cell carcinoma . 4 . Active alcohol drug abuse severity sufficient place subject risk . 5 . Evidence clinically significant cardiovascular , renal , hepatic , gastrointestinal ( paralytic ileus ) , psychiatric disease , determine medical history , clinical laboratory test , Electrocardiogram ( ECG ) result , physical examination , would place subject risk upon exposure study medication could confound analysis and/or interpretation study result . 6 . Abnormal aspartate aminotransferase ( AST ; SGOT ) , alanine aminotransferase ( ALT ; SGPT ) , alkaline phosphatase level ( &gt; 3 time upper limit normal ) abnormal total bilirubin and/or creatinine level ( ) ( outside reference range ) . 7 . Surgery complete less 2 month prior start Screening Period , plan surgery 12week Doubleblind Phase , pharmacological nonpharmacological intervention would influence pain study ( include chemotherapy ) preclude completion study . 8 . Subjects take , take , naloxone experimental drug le 30 day prior start Screening Period . 9 . Subjects history 2 great low back surgery . Amendment No . 1 , date 28Sep2004 prior FPFV , change exclusion criterion bullet 4 : Active alcohol drug abuse . Amendment No . 2 , date 25May2005 , change exclusion criterion bullet 9 : Subjects history le 2 low back surgery . ( See Section 9.8.1 ) Any amendment protocol include Appendix 16.1.1.1 . Subjects meet inclusion/exclusion criterion could allow enter study , follow discussion Investigator CRO/Sponsor , write permission obtain CRO/Sponsor . In instance , write permission file investigational site CRO/Sponsor .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2013</verification_date>
</DOC>